Novo Nordisk A/S (NONOF)
USD 69.9
(6.72%)
USD 69.9
(6.72%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 196.49 Billion DKK | 32.32% |
| 2022 | 148.5 Billion DKK | 26.77% |
| 2021 | 117.14 Billion DKK | 10.5% |
| 2020 | 106.01 Billion DKK | 4.0% |
| 2019 | 101.93 Billion DKK | 8.19% |
| 2018 | 94.21 Billion DKK | 0.16% |
| 2017 | 94.06 Billion DKK | -0.56% |
| 2016 | 94.59 Billion DKK | 3.12% |
| 2015 | 91.73 Billion DKK | 23.56% |
| 2014 | 74.24 Billion DKK | 6.93% |
| 2013 | 69.43 Billion DKK | 7.54% |
| 2012 | 64.56 Billion DKK | 20.1% |
| 2011 | 53.75 Billion DKK | 9.49% |
| 2010 | 49.09 Billion DKK | 20.81% |
| 2009 | 40.64 Billion DKK | 14.37% |
| 2008 | 35.53 Billion DKK | 10.75% |
| 2007 | 32.08 Billion DKK | 10.02% |
| 2006 | 29.16 Billion DKK | 18.8% |
| 2005 | 24.54 Billion DKK | 16.19% |
| 2004 | 21.12 Billion DKK | 10.32% |
| 2003 | 19.15 Billion DKK | 3.36% |
| 2002 | 18.52 Billion DKK | 4.38% |
| 2001 | 17.75 Billion DKK | 8.01% |
| 2000 | 16.43 Billion DKK | 3.4% |
| 1999 | 15.89 Billion DKK | 17.54% |
| 1998 | 13.52 Billion DKK | 10.28% |
| 1997 | 12.26 Billion DKK | 14.21% |
| 1996 | 10.73 Billion DKK | 8.63% |
| 1995 | 9.88 Billion DKK | 2.06% |
| 1994 | 9.68 Billion DKK | 43.73% |
| 1993 | 6.73 Billion DKK | -17.27% |
| 1992 | 8.14 Billion DKK | 61.78% |
| 1991 | 5.03 Billion DKK | 19.67% |
| 1990 | 4.2 Billion DKK | 9.15% |
| 1989 | 3.85 Billion DKK | 32.3% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 55.43 Billion DKK | -0.74% |
| 2024 Q2 | 57.78 Billion DKK | 4.24% |
| 2023 FY | 196.49 Billion DKK | 32.32% |
| 2023 Q3 | 49.01 Billion DKK | 5.54% |
| 2023 Q4 | 55.84 Billion DKK | 13.94% |
| 2023 Q1 | 45.18 Billion DKK | 13.44% |
| 2023 Q2 | 46.44 Billion DKK | 2.79% |
| 2022 Q1 | 35.11 Billion DKK | 9.42% |
| 2022 Q3 | 38.36 Billion DKK | 9.01% |
| 2022 FY | 148.5 Billion DKK | 26.77% |
| 2022 Q2 | 35.19 Billion DKK | 0.23% |
| 2022 Q4 | 39.83 Billion DKK | 3.82% |
| 2021 Q3 | 29.56 Billion DKK | 7.53% |
| 2021 Q4 | 32.09 Billion DKK | 8.55% |
| 2021 Q1 | 27.99 Billion DKK | 5.56% |
| 2021 Q2 | 27.49 Billion DKK | -1.78% |
| 2021 FY | 117.14 Billion DKK | 10.5% |
| 2020 Q4 | 26.51 Billion DKK | 2.9% |
| 2020 Q2 | 25.23 Billion DKK | -11.43% |
| 2020 Q1 | 28.48 Billion DKK | 5.57% |
| 2020 Q3 | 25.77 Billion DKK | 2.13% |
| 2020 FY | 106.01 Billion DKK | 4.0% |
| 2019 Q4 | 26.98 Billion DKK | 7.07% |
| 2019 Q1 | 24.55 Billion DKK | -2.07% |
| 2019 Q2 | 25.18 Billion DKK | 2.56% |
| 2019 Q3 | 25.2 Billion DKK | 0.06% |
| 2019 FY | 101.93 Billion DKK | 8.19% |
| 2018 Q2 | 23.05 Billion DKK | 1.42% |
| 2018 Q4 | 25.07 Billion DKK | 7.42% |
| 2018 Q1 | 22.73 Billion DKK | -2.4% |
| 2018 FY | 94.21 Billion DKK | 0.16% |
| 2018 Q3 | 23.34 Billion DKK | 1.27% |
| 2017 Q3 | 22.34 Billion DKK | -7.79% |
| 2017 FY | 94.06 Billion DKK | -0.56% |
| 2017 Q2 | 24.22 Billion DKK | 0.12% |
| 2017 Q4 | 23.29 Billion DKK | 4.25% |
| 2017 Q1 | 24.2 Billion DKK | -1.84% |
| 2016 Q3 | 23.55 Billion DKK | 0.59% |
| 2016 Q4 | 24.65 Billion DKK | 4.68% |
| 2016 Q1 | 22.97 Billion DKK | -5.32% |
| 2016 Q2 | 23.41 Billion DKK | 1.9% |
| 2016 FY | 94.59 Billion DKK | 3.12% |
| 2015 Q4 | 24.26 Billion DKK | 5.77% |
| 2015 Q3 | 22.94 Billion DKK | -1.1% |
| 2015 Q1 | 21.32 Billion DKK | 3.59% |
| 2015 Q2 | 23.2 Billion DKK | 8.79% |
| 2015 FY | 91.73 Billion DKK | 23.56% |
| 2014 Q3 | 18.82 Billion DKK | 4.82% |
| 2014 FY | 74.24 Billion DKK | 6.93% |
| 2014 Q1 | 16.87 Billion DKK | -7.77% |
| 2014 Q2 | 17.95 Billion DKK | 6.41% |
| 2014 Q4 | 20.58 Billion DKK | 9.37% |
| 2013 Q4 | 18.29 Billion DKK | 7.72% |
| 2013 FY | 69.43 Billion DKK | 7.54% |
| 2013 Q1 | 16.37 Billion DKK | -8.06% |
| 2013 Q2 | 17.77 Billion DKK | 8.55% |
| 2013 Q3 | 16.98 Billion DKK | -4.43% |
| 2012 Q1 | 14.34 Billion DKK | -4.33% |
| 2012 Q4 | 17.8 Billion DKK | 8.86% |
| 2012 FY | 64.56 Billion DKK | 20.1% |
| 2012 Q3 | 16.36 Billion DKK | 1.97% |
| 2012 Q2 | 16.04 Billion DKK | 11.82% |
| 2011 FY | 53.75 Billion DKK | 9.49% |
| 2011 Q2 | 12.9 Billion DKK | 2.59% |
| 2011 Q3 | 13.28 Billion DKK | 2.94% |
| 2011 Q4 | 14.99 Billion DKK | 12.93% |
| 2011 Q1 | 12.57 Billion DKK | -3.55% |
| 2010 Q1 | 10.98 Billion DKK | 5.34% |
| 2010 Q2 | 12.42 Billion DKK | 13.12% |
| 2010 Q3 | 12.64 Billion DKK | 1.79% |
| 2010 Q4 | 13.03 Billion DKK | 3.09% |
| 2010 FY | 49.09 Billion DKK | 20.81% |
| 2009 FY | 40.64 Billion DKK | 14.37% |
| 2009 Q3 | 9.83 Billion DKK | -5.38% |
| 2009 Q2 | 10.39 Billion DKK | 4.01% |
| 2009 Q1 | 9.99 Billion DKK | -1.67% |
| 2009 Q4 | 10.42 Billion DKK | 6.05% |
| 2008 Q4 | 10.15 Billion DKK | 17.7% |
| 2008 FY | 35.53 Billion DKK | 10.75% |
| 2008 Q2 | 8.55 Billion DKK | 4.49% |
| 2008 Q1 | 8.19 Billion DKK | -2.52% |
| 2008 Q3 | 8.63 Billion DKK | 0.84% |
| 2007 Q2 | 8.2 Billion DKK | 9.5% |
| 2007 Q4 | 8.4 Billion DKK | 5.23% |
| 2007 FY | 32.08 Billion DKK | 10.02% |
| 2007 Q1 | 7.49 Billion DKK | -5.11% |
| 2007 Q3 | 7.98 Billion DKK | -2.69% |
| 2006 Q1 | 6.53 Billion DKK | -4.99% |
| 2006 FY | 29.16 Billion DKK | 18.8% |
| 2006 Q4 | 7.89 Billion DKK | 9.01% |
| 2006 Q2 | 7.47 Billion DKK | 14.38% |
| 2006 Q3 | 7.24 Billion DKK | -3.09% |
| 2005 Q4 | 6.88 Billion DKK | 6.97% |
| 2005 FY | 24.54 Billion DKK | 16.19% |
| 2005 Q3 | 6.43 Billion DKK | 6.0% |
| 2005 Q2 | 6.06 Billion DKK | 17.19% |
| 2005 Q1 | 5.17 Billion DKK | -10.29% |
| 2004 Q4 | 5.77 Billion DKK | 7.29% |
| 2004 FY | 21.12 Billion DKK | 10.32% |
| 2004 Q3 | 5.37 Billion DKK | 7.54% |
| 2004 Q1 | 4.68 Billion DKK | -35.38% |
| 2004 Q2 | 5 Billion DKK | 6.7% |
| 2003 Q1 | 6.09 Billion DKK | -8.86% |
| 2003 Q4 | 7.25 Billion DKK | 8.07% |
| 2003 Q3 | 6.71 Billion DKK | 3.56% |
| 2003 FY | 19.15 Billion DKK | 3.36% |
| 2003 Q2 | 6.48 Billion DKK | 6.45% |
| 2002 Q1 | 6.02 Billion DKK | -7.42% |
| 2002 Q2 | 5.27 Billion DKK | -12.32% |
| 2002 Q3 | 6.44 Billion DKK | 22.11% |
| 2002 Q4 | 6.68 Billion DKK | 3.67% |
| 2002 FY | 18.52 Billion DKK | 4.38% |
| 2001 Q1 | 5.34 Billion DKK | 146.84% |
| 2001 FY | 17.75 Billion DKK | 8.01% |
| 2001 Q4 | 6.5 Billion DKK | -2.24% |
| 2001 Q3 | 6.65 Billion DKK | 15.78% |
| 2001 Q2 | 5.74 Billion DKK | 7.47% |
| 2000 Q2 | 6.48 Billion DKK | 16.57% |
| 2000 Q3 | 15.34 Billion DKK | 136.62% |
| 2000 FY | 16.43 Billion DKK | 3.4% |
| 2000 Q4 | 2.16 Billion DKK | -85.88% |
| 2000 Q1 | 5.56 Billion DKK | 0.01% |
| 1999 Q2 | 5.02 Billion DKK | 8.45% |
| 1999 Q4 | 5.56 Billion DKK | -4.48% |
| 1999 FY | 15.89 Billion DKK | 17.54% |
| 1999 Q1 | 4.63 Billion DKK | -5.0% |
| 1999 Q3 | 5.82 Billion DKK | 15.94% |
| 1998 Q2 | 4.56 Billion DKK | 8.95% |
| 1998 Q1 | 4.19 Billion DKK | -10.56% |
| 1998 Q4 | 4.87 Billion DKK | -3.17% |
| 1998 FY | 13.52 Billion DKK | 10.28% |
| 1998 Q3 | 5.03 Billion DKK | 10.22% |
| 1997 Q4 | 4.68 Billion DKK | 8.61% |
| 1997 Q2 | 4.12 Billion DKK | 13.72% |
| 1997 Q1 | 3.62 Billion DKK | -13.67% |
| 1997 FY | 12.26 Billion DKK | 14.21% |
| 1997 Q3 | 4.31 Billion DKK | 4.63% |
| 1996 FY | 10.73 Billion DKK | 8.63% |
| 1996 Q4 | 4.2 Billion DKK | 14.51% |
| 1996 Q3 | 3.66 Billion DKK | 4.6% |
| 1996 Q2 | 3.5 Billion DKK | 2.12% |
| 1996 Q1 | 3.43 Billion DKK | 0.7% |
| 1995 FY | 9.88 Billion DKK | 2.06% |
| 1995 Q4 | 3.41 Billion DKK | 6.0% |
| 1995 Q3 | 3.21 Billion DKK | -9.94% |
| 1995 Q2 | 3.57 Billion DKK | 6.01% |
| 1995 Q1 | 3.37 Billion DKK | -5.24% |
| 1994 Q1 | 3.11 Billion DKK | -26.64% |
| 1994 FY | 9.68 Billion DKK | 43.73% |
| 1994 Q4 | 3.55 Billion DKK | 5.4% |
| 1994 Q3 | 3.37 Billion DKK | -1.4% |
| 1994 Q2 | 3.42 Billion DKK | 10.02% |
| 1993 Q4 | 4.24 Billion DKK | 35.46% |
| 1993 Q2 | 3 Billion DKK | 14.37% |
| 1993 Q3 | 3.13 Billion DKK | 4.25% |
| 1993 Q1 | 2.62 Billion DKK | -3.24% |
| 1993 FY | 6.73 Billion DKK | -17.27% |
| 1992 Q2 | 2.8 Billion DKK | 5.54% |
| 1992 Q1 | 2.66 Billion DKK | -9.6% |
| 1992 Q4 | 2.71 Billion DKK | 5.79% |
| 1992 FY | 8.14 Billion DKK | 61.78% |
| 1992 Q3 | 2.56 Billion DKK | -8.67% |
| 1991 Q4 | 2.94 Billion DKK | 23.05% |
| 1991 Q1 | 2.27 Billion DKK | -2.13% |
| 1991 Q2 | 2.24 Billion DKK | -1.2% |
| 1991 Q3 | 2.39 Billion DKK | 6.4% |
| 1991 FY | 5.03 Billion DKK | 19.67% |
| 1990 Q3 | 2.02 Billion DKK | -0.11% |
| 1990 Q4 | 2.32 Billion DKK | 14.61% |
| 1990 Q2 | 2.03 Billion DKK | 4.7% |
| 1990 FY | 4.2 Billion DKK | 9.15% |
| 1990 Q1 | 1.94 Billion DKK | -9.53% |
| 1989 Q3 | 1.74 Billion DKK | -0.53% |
| 1989 Q1 | 1.97 Billion DKK | 20.78% |
| 1989 Q2 | 1.75 Billion DKK | -11.07% |
| 1989 Q4 | 2.14 Billion DKK | 22.72% |
| 1989 FY | 3.85 Billion DKK | 32.3% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | 2371708005.854% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -1309960.671% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -2006189.565% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -298953161.928% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -1678492.175% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -164873.553% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 575391022.401% |
| Marizyme, Inc. | 457.7 Thousand USD | -42930890.033% |
| Genus plc | 178.7 Million USD | -109858.59% |
| Pharming Group N.V. | 220.1 Million USD | -89174.161% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -315777870.623% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -47906474.184% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1786327372.727% |
| ContraFect Corporation | -154 Thousand USD | 127594905.195% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -255984058.622% |
| IMV Inc. | -962.29 Thousand USD | 20419554.265% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 50708614.301% |
| ONE Bio Corp. | 20.12 Million USD | -976256.245% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -487906.954% |
| Mesoblast Limited | -35.16 Million USD | 558835.214% |
| MultiCell Technologies, Inc. | 49.32 USD | -398410381084.104% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -695337.976% |
| Genscript Biotech Corporation | 409.55 Million USD | -47878.162% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -6334493774.919% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1273962755.602% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 17212855.744% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -280708471.429% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 158144501.252% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 3968013024.071% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 392992100.0% |
| Arch Therapeutics, Inc. | -2439.00 USD | 8056416664.166% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -139854704.27% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -401832210.838% |
| Q BioMed Inc. | -8988.00 USD | 2186203927.325% |
| GB Sciences, Inc. | -624.00 USD | 31489743689.744% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 228409455.094% |
| CSL Limited | 7.56 Billion USD | -2498.81% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -442879.449% |
| Enzolytics Inc. | 30.7 Thousand USD | -639885271.89% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -40730115.387% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 201503458.458% |
| argenx SE | 1.1 Billion USD | -17626.601% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 761771.447% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 94469230869.231% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 38191000.08% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 2218789621.229% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -31827093.448% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 234345172.69% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -19888541.583% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -2044390.688% |
| Kadimastem Ltd | -630.13 Thousand USD | 31183110.706% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | -1273792.701% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1660295832.995% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 407169747.112% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -111291245.718% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -111291245.718% |
| Affymax, Inc. | 1.35 Million USD | -14478551.108% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -4264136.111% |
| CytoDyn Inc. | -29 Thousand USD | 677572513.793% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -43661505.669% |
| SYBLEU INC | 11.69 Thousand USD | -1680027259.781% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 61499848.049% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 52679992.761% |
| Neutra Corp. | 14.33 Thousand USD | -1370742836.868% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 239629368.293% |
| PureTech Health plc | -1.6 Million USD | 12258116.22% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 19625443.076% |
| IXICO plc | 3.27 Million USD | -6008951.988% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 28313644.669% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 10971400.949% |
| CSL Limited | 7.7 Billion USD | -2450.24% |
| Cellectis S.A. | 18 Thousand USD | -1091644344.444% |